<DOC>
	<DOCNO>NCT00003163</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness peripheral stem cell transplantation treat patient multiple myeloma B-cell cancer .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma Other B-cell Cancers</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy myeloablative therapy autologous hematopoietic stem cell transplantation patient multiple myeloma B-cell malignancy . - Determine efficacy pretransplantation prognostic factor associate myeloablative therapy patient . - Determine engraftment kinetics granulocytes platelet , well blood product transfusion requirement follow hematopoietic stem cell transplantation . OUTLINE : Patients must hematopoietic stem cell procurement complete prior myeloablative therapy . Patients receive high dose chemotherapy autologous hematopoietic stem cell transplantation supportive care . Melphalan administer one dose day -1 least 12 hour stem cell infusion . Peripheral blood stem cell and/or bone marrow reinfused day 0 . Filgrastim ( G-CSF ) sargramostim ( GM-CSF ) administer begin day 1 posttransplantation continue blood count recover . Patients candidate tandem transplant may receive melphalan plus total body irradiation ( TBI ) . Melphalan administer IV day -4 . Total body irradiation administer three time day day -3 -2 twice day -1 . At least 4 hour must elapse treatment . Hematopoietic stem cell reinfused day -1 upon completion TBI day 0 . If patient ineligible melphalan plus TBI , alternative single high dose regimen melphalan plus cyclophosphamide administer . Melphalan , patient , give two equal dos day -4 follow two consecutive day cyclophosphamide day -3 -2 . Hematopoietic stem cell reinfused day 0 . A second transplant may consider , preferably 3 6 month first transplant . The preferred regimen second transplant melphalan alone melphalan plus TBI describe . The alternative regimen second dose therapy melphalan alone melphalan plus cyclophosphamide . For patient receive melphalan alone , melphalan administer one dose day -1 least 12 hour stem cell infusion . Hematopoietic stem cell reinfused day 0 alternative regimen . Patients follow response treatment minimum 4 week periodically survival . PROJECTED ACCRUAL : A minimum 10 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma Bcell malignancy include nonHodgkin 's lymphoma , Waldenstrom 's macroglobulinemia , amyloidosis NonHodgkin 's lymphoma Tcell immunophenotypes include PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 2,000/mm^3 ( unless due disease ) Platelet count least 100,000/mm^3 ( unless due disease ) Hepatic : Not specify Renal : Not specify Cardiovascular : LVEF least 40 % Pulmonary : DLCO FVC FEV1 least 50 % predicted unless due restriction volume loss secondary disease Other : HIV negative No overt infection unexplained fever require broad spectrum antibiotic Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior biologic therapy Chemotherapy : At least 2 week since prior chemotherapy recover Endocrine therapy : At least 2 week since prior endocrine therapy Concurrent steroid allow Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>